SHIAW-YIH LIN to Cell Line, Tumor
This is a "connection" page, showing publications SHIAW-YIH LIN has written about Cell Line, Tumor.
Connection Strength
0.554
-
A Gene Expression Signature to Predict Nucleotide Excision Repair Defects and Novel Therapeutic Approaches. Int J Mol Sci. 2021 May 08; 22(9).
Score: 0.067
-
Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer. Cancer Cell. 2020 03 16; 37(3):371-386.e12.
Score: 0.062
-
mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer. Clin Cancer Res. 2016 Apr 01; 22(7):1699-712.
Score: 0.046
-
Genome-wide transcriptome profiling of homologous recombination DNA repair. Nat Commun. 2014; 5:3361.
Score: 0.040
-
Zinc finger protein 668 interacts with Tip60 to promote H2AX acetylation after DNA damage. Cell Cycle. 2013 Jul 01; 12(13):2033-41.
Score: 0.039
-
BRIT1 regulates p53 stability and functions as a tumor suppressor in breast cancer. Carcinogenesis. 2013 Oct; 34(10):2271-80.
Score: 0.039
-
ZNF668 functions as a tumor suppressor by regulating p53 stability and function in breast cancer. Cancer Res. 2011 Oct 15; 71(20):6524-34.
Score: 0.034
-
BRIT1/MCPH1 links chromatin remodelling to DNA damage response. Nat Cell Biol. 2009 Jul; 11(7):865-72.
Score: 0.030
-
Differential regulation of centrosome integrity by DNA damage response proteins. Cell Cycle. 2008 Jul 15; 7(14):2225-33.
Score: 0.027
-
BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. Cancer Cell. 2006 Aug; 10(2):145-57.
Score: 0.024
-
BRIT1/MCPH1 is a DNA damage responsive protein that regulates the Brca1-Chk1 pathway, implicating checkpoint dysfunction in microcephaly. Proc Natl Acad Sci U S A. 2005 Oct 18; 102(42):15105-9.
Score: 0.023
-
Combined Inhibition of Rad51 and Wee1 Enhances Cell Killing in HNSCC Through Induction of Apoptosis Associated With Excessive DNA Damage and Replication Stress. Mol Cancer Ther. 2021 07; 20(7):1257-1269.
Score: 0.017
-
Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy. Cancer Cell. 2019 06 10; 35(6):851-867.e7.
Score: 0.015
-
PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non-small-cell lung cancer. Int J Cancer. 2019 03 01; 144(5):1092-1103.
Score: 0.014
-
BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. Cancer Cell. 2018 03 12; 33(3):401-416.e8.
Score: 0.014
-
Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers. Sci Transl Med. 2017 05 31; 9(392).
Score: 0.013
-
MicroPET/CT Imaging of AXL Downregulation by HSP90 Inhibition in Triple-Negative Breast Cancer. Contrast Media Mol Imaging. 2017; 2017:1686525.
Score: 0.013
-
Tyrosine 370 phosphorylation of ATM positively regulates DNA damage response. Cell Res. 2015 Feb; 25(2):225-36.
Score: 0.011
-
Dual functions of the homeoprotein DLX4 in modulating responsiveness of tumor cells to topoisomerase II-targeting drugs. Cancer Res. 2013 Jan 15; 73(2):1000-10.
Score: 0.009
-
FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis. 2012 Oct; 33(10):1843-53.
Score: 0.009
-
siRNA-based targeting of cyclin E overexpression inhibits breast cancer cell growth and suppresses tumor development in breast cancer mouse model. PLoS One. 2010 Sep 20; 5(9):e12860.
Score: 0.008